Skip to main content
Clinical Trials/NCT03870360
NCT03870360
Active, not recruiting
Not Applicable

Health Promotion in the Prevention of Anxiety and Depression: the Happy Older Latinos Are Active (HOLA Study)

University of Miami1 site in 1 country240 target enrollmentNovember 1, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Depression
Sponsor
University of Miami
Enrollment
240
Locations
1
Primary Endpoint
Incidence of generalized anxiety disorder
Status
Active, not recruiting
Last Updated
5 months ago

Overview

Brief Summary

The purpose of this study is to look at the best ways to prevent anxiety and depression in older Latino adults who are at risk for developing anxiety and depression. Participants will be randomized to either a health promotion intervention or a healthy lifestyles education program.

Detailed Description

Given the prevalence and morbidity of depression in later life, the inadequacies of current treatment approaches for averting years living with disability, the inequities in access to the mental health care delivery system, and the workforce shortages to meet the mental health needs of older Latinos, development and testing of innovative strategies to prevent depression and anxiety are of great public health significance and have the potential to change practice.

Registry
clinicaltrials.gov
Start Date
November 1, 2022
End Date
June 1, 2026
Last Updated
5 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Daniel Enrique Jimenez

Assistant Professor

University of Miami

Eligibility Criteria

Inclusion Criteria

  • Latino (self-identified);
  • Subthreshold depression defined as a score ≥ 5 on the Patient Health Questionnaire (PHQ-9), OR subthreshold anxiety as defined as a score ≥ 5 on the GAD-7;
  • Do not meet criteria for current MDD or GAD as indicated by the Mini International Neuropsychiatric Inventory (MINI);
  • Voluntary informed consent for participation in the study by the participant or by the participant's legally designated guardian or conservator;
  • Medical clearance for participation in a health promotion intervention by a physician, physician's assistant, or nurse practitioner;
  • Not taking steroidal or anti-inflammatory medication (including NSAIDs) within 2 weeks of treatment randomization;
  • Expect to be resident in Miami for the subsequent 2 years.

Exclusion Criteria

  • Have met criteria for major depressive disorder or generalized anxiety disorder within the past 12 months;
  • Have met criteria for alcohol or other substance abuse disorders within the past 12 months;
  • Are currently receiving antidepressant medication or participating in other mental health treatment;
  • Have a lifetime history of bipolar disorder or other psychotic disorder including major depression with psychotic features;
  • Have a diagnosis of any neurodegenerative disorder or dementia (Parkinson's disease, Alzheimer's, vascular, frontotemporal dementia, etc.) or significant cognitive impairment as indicated by a Mini Mental Status Exam (MMSE) score \<24;
  • Are current tobacco smokers since smoking influences systemic inflammation;
  • Have contraindications to physical activity outlined in the American College of Sports Medicine standards;
  • Have high suicide risk, i.e., intent or plan to attempt suicide in the near future (a response of "yes" to questions 3, 4, and/or 5 on the Paykel Questionnaire;
  • Are unable to complete 10 m walk test;
  • Currently residing in a nursing or group home;

Outcomes

Primary Outcomes

Incidence of generalized anxiety disorder

Time Frame: 2 years

As measured by the Structured Clinical Interview for the Diagnostic and Statistical Manual 5th edition (SCID-5), a structured clinical interview used for diagnosis.

Recurrence of major depression disorder

Time Frame: 2 years

As measured by the SCID-5, a structured clinical interview used for diagnosis.

Change in risk factors for major depressive disorder (MDD)

Time Frame: Baseline, 16 weeks, 6, 12, 18, and 24 months

As measured by the Beck Depression Inventory that has a range of scores from 0-63 with scores of 0-9 being minimal depression, 10-18 mild depression, 19-29 moderate depression, and 30-63 severe depression.

Change in risk factors for generalized anxiety disorder (GAD)

Time Frame: Baseline, 16 weeks, 6, 12, 18, and 24 months

As measured by the Beck Anxiety Inventory that has a range of scores from 0-63 with scores 0-21 low anxiety, 22-35 moderate anxiety, and 36+ potentially concerning levels

Incidence of major depression disorder

Time Frame: 2 years

As measured by the SCID-5, a structured clinical interview used for diagnosis.

Recurrence of generalized anxiety disorder

Time Frame: 2 years

As measured by the SCID-5, a structured clinical interview used for diagnosis.

Secondary Outcomes

  • Change in anti-inflammatory markers(Baseline, 16 weeks, 12, and 24 months)
  • Change in pro-inflammatory markers(Baseline, 16 weeks, 12, and 24 months)
  • Change in physical functioning as measured by the physical performance battery(Baseline, 16 weeks, 6, 12, 18, and 24 months)
  • Change in quality of life(Baseline, 16 weeks, 6, 12, 18, and 24 months)

Study Sites (1)

Loading locations...

Similar Trials